1 unknown, 1 withdrawn. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Vaxxinity, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine - COVID-19 Vaccines | Phase 3 | Unknown | Vaxxinity, Inc. | 944 | 2022-03-16 | 2022-10-14 |
| A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine UB-612, Placebo - Covid-19, SARS-CoV-2 | Phase 2 / Phase 3 | Withdrawn | Vaxxinity, Inc. | 2021-02-01 | 2022-04-04 |
COVID-19 (2) · Coronavirus Infections (1)
UB-612 COVID-19 vaccine (2) · BIBP COVID-19 vaccine (1) · BNT162 Vaccine (1)
Panama (1) · Philippines (1) · United States (1)
Gray Heppner (1)